Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GAPDHP24 stands for "glyceraldehyde-3-phosphate dehydrogenase pseudogene 24," a non-functional, non-protein-coding pseudogene in the human genome with high sequence homology to the functional GAPDH gene. Unlike GAPDH, which encodes an essential glycolytic enzyme and has multiple cellular roles, pseudogenes like GAPDHP24 do not produce active proteins, do not participate in metabolism, and are not studied as therapeutic drug targets. While some pseudogenes can have minor regulatory effects at the RNA level, there is no evidence that GAPDHP24 has biological function or relevance in health or disease[3]. Key clarifications: - If you intend information on the true metabolic enzyme, the correct entry would be "glyceraldehyde-3-phosphate dehydrogenase" (GAPDH), a major glycolytic enzyme with well-defined biological functions and some disease relevance[1][2][3][4]. - GAPDHP24 is not the same as GAPDH, is not a drug target, and has no known function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 24 (GAPDHP24).